Subject(s)
COVID-19/epidemiology , Cardiology/methods , Laboratories , Nuclear Medicine/methods , Pandemics , Practice Guidelines as Topic , Societies, Medical , Humans , Risk , SafetySubject(s)
Betacoronavirus , Cardiology , Coronavirus Infections/epidemiology , Nuclear Medicine , Pneumonia, Viral/epidemiology , Practice Guidelines as Topic , COVID-19 , COVID-19 Testing , Cardiology/education , Clinical Laboratory Techniques , Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Humans , Laboratories , Nuclear Medicine/education , Pandemics/prevention & control , Personal Protective Equipment , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Societies, MedicalABSTRACT
BACKGROUND: Regadenoson (Reg) is being administered with increasing frequency either at peak exercise (ExPeak-Reg) or during a slow-down/walking recovery state (ExRec-Reg) rather than at rest (Rest-Reg). The aim of this study was to compare the clinical response of ExPeak-Reg, ExRec-Reg, and Rest-Reg. METHODS: We compared 531 patients divided equally between Rest-Reg, ExPeak-Reg, and ExRec-Reg matched for age, sex, and BMI. RESULTS: The average systolic blood pressure (SBP) rise following Reg was modest, but there was considerable heterogeneity and the ExPeak-Reg group had a higher percentage of patients who had a SBP rise of 40 mm Hg or a fall of 20 mm Hg than either the ExRec-Reg or the Rest-Reg groups (≥40 mm Hg rise 6.8%, 1.7%, and 1.7%, respectively) (P < .02) (≥20 mm Hg fall 15.8%, 13.0%, and 7.3%, respectively) (P < .05). Chest discomfort, nausea, dizziness, and interfering abdominal radiotracer activity were less common in both exercise Reg groups compared to Rest-Reg (P < .05). CONCLUSION: Regadenoson injected at peak of symptom-limited exercise was generally well tolerated, but some patients had a significant rise or drop in SBP. There is no apparent advantage of administering regadenoson at peak exercise rather than during walk recovery, and the latter approach may have a greater safety margin.
